

Universal Biosensors, Inc.
ABN 51 121 559 993

1 Corporate Avenue
Rowville Victoria 3149
Australia

Telephone: +61 3 9213 9000
Facsimile: +61 3 9213 6490
Email: info@universalbiosensors.com
www.universalbiosensors.com



Universal Biosensors

30 June 2016

Universal Biosensors Appoints Craig Coleman as Non-Executive Director

Universal Biosensors, Inc. (ASX: UBI) today announced the appointment of Mr. Craig Coleman as a non-executive director to the Board of Universal Biosensors. This appointment continues the board renewal process which has occurred over recent years, with the appointment of Ms. Judith Smith in 2015 and Mr. David Hoey in 2016.

Mr. Coleman's career of 30 years has spanned banking and finance, corporate advisory and funds management. During his executive career, he has been a Managing Director of a publicly listed company (Home Building Society Ltd) and prior to this, held a number of senior executive positions with ANZ Banking Group Ltd, including Managing Director Banking Products, Managing Director Wealth Management, Non-Executive Director E*TRADE Australia Ltd and Head of Retail Banking New Zealand.

Craig is currently the Executive Chairman of Viburnum Funds, an Australian-based specialist investment manager founded in 2007 with investments in private equity funds, strategic equities and Australian equities. Viburnum Funds currently holds around 14% of UBI's securities.

Mr. Coleman currently retains non-executive directorship positions with publicly listed entities, Bell Financial Group Ltd, Pulse Health Ltd and Rubik Financial Ltd. Craig holds a Bachelor of Commerce from the University of Western Australia.

"Craig's extensive investment management experience will be an asset to the company," said UBI Chairman, Mr Andrew Denver. "We will benefit from his strong background in the finance and corporate advisory industry, as we strive to increase our shareholder value. We look forward to his contribution to UBI."

Mr. Coleman has also been appointed as Chair of the Remuneration & Nomination Committee, which is now comprised of Mr. Marshall Heinberg, Mr. David Hoey and Mr. Andrew Denver.

Ends

Enquiries:
Andrew Denver +61 3 9213 9000

About Universal Biosensors

For additional information in relation to Universal Biosensors, refer to
<http://www.universalbiosensors.com>.

Universal Biosensors is a specialist medical diagnostics company, founded in 2001, that is focused on the development, manufacture and commercialisation of a range of in vitro diagnostic tests for point-of-care use. These tests capitalise on a technology platform which uses a novel electrochemical cell that can be adapted for multiple analytes and provide for enhanced measurements in whole blood.

Under applicable United States securities laws all of the shares of our common stock are "restricted securities" as that term is defined in Rule 144 under the Securities Act of 1933, as amended (Securities Act). Restricted securities may be resold in the public market to United States persons as defined in Regulation S only if registered for resale or if they qualify for an exemption from registration under the Securities Act. We have not agreed to register any of our common stock for resale by security holders.